Program
londamocitinib
Also written as “AZD4604”, “AZD4604 for inhalation via DPI” and “AZD4604 Inhalation Powder, 1 mg”.
Its studies are mostly in Asthma, led by AstraZeneca.
Furthest: phase 2, since Aug 25, 20236 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 60 open or running | phase 2since Aug 25, 2023 | Feb 12, 2021 | none ahead |
Also a collaborator on its studies: parexel and quotient-sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 12, 2021First study: phase 1 study in AsthmaFirst studyNCT04769869 · 110 enrolled · United Kingdom
- Aug 25, 2023Phase 2 study in AsthmaNCT06020014 · 339 enrolled · United States, Argentina, Brazil and more
- Nov 27, 2023Phase 1 study in AsthmaNCT06157255 · 8 enrolled · United Kingdom
- May 24, 2024Phase 2 study in AsthmaNCT06435273 · 36 enrolled · Canada, Denmark, Germany and more
- Jul 5, 2024Phase 1 study in Healthy ParticipantsNCT06519968 · 56 enrolled · United Kingdom
- Dec 10, 2024Phase 1 study in AsthmaNCT06732882 · 28 enrolled · Germany, United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06732882Asthma · Germany, United Kingdom | 1 | Completed | May 29, 2025 | 28 |
| NCT06519968Healthy Participants · United Kingdom | 1 | Completed | Dec 27, 2024 | 56 |
| NCT06435273Asthma · Canada, Denmark, Germany and more | 2 | Completed | Oct 15, 2025 | 36 |
| NCT06157255Asthma · United Kingdom | 1 | Completed | May 20, 2024 | 8 |
| NCT06020014Asthma · United States, Argentina, Brazil and more | 2 | Completed | Oct 28, 2025 | 339 |
| NCT04769869Asthma · United Kingdom | 1 | Completed | Jan 24, 2023 | 110 |
How it is read
Names in the registry
- “AZD4604”, 4 entries
- “AZD4604 for inhalation via DPI”, 2 entries
- “AZD4604 Inhalation Powder, 1 mg”, 1 entry
- “[14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL)”, 1 entry
- “[14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.